Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 692-702

  Loisel Meyer, Severine ^a   Felizardo, Tania ^a   Mariotti, Jacopo ^d   Mossoba, Miriam E ^d   Foley, Jason E ^d   Kammerer, Robert ^e,f   Mizue, Nobuo ^a   Keefe, Robert ^g   McCart, J Andrea ^b,c   Zimmermann, Wolfgang ^e   Dropulic, Boro ^g   Fowler, Daniel H ^d   Medin, Jeffrey A ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

^f FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^g Lentigen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; TETRAMER;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYMPH NODE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STOMACH CARCINOMA; T LYMPHOCYTE; TISSUE SECTION; TRANSGENIC MOUSE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; C57BL MOUSE; CELL CULTURE; EVALUATION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INJECTION; LENTIVIRINAE; METHODOLOGY; NEOPLASM; PATHOLOGY; TUMOR VOLUME;

ANIMALS; B-LYMPHOCYTES; CARCINOEMBRYONIC ANTIGEN; CELLS, CULTURED; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INJECTIONS; LENTIVIRUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 66449130673     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0769     Document Type: Article

References (35)

1. Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 2006;5:717-732 (Pubitemid 46021052)
2. Loisel-Meyer S, Foley R, Medin JA. Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 2008;13:3202-3214
3. He Y, Zhang J, Mi Z, Robbins P, Falo LD, Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005;174:3808-3817 (Pubitemid 40354094)
4. Lopes L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapy strategy. Cancer Immunol Immunother 2006;55:1011-1016 (Pubitemid 43673592)
5. Mossoba ME, Walia JS, Rasaiah VI, et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 2008;16:607-617
6. Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004;64:1490-1495 (Pubitemid 38235621)
7. Compte M, Banco B, Serrano F, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007;14:380-388 (Pubitemid 46425780)
8. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007;14:847-862 (Pubitemid 46780068)
9. VandenDriessche T, Thorrez L, Naldini L, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002;100:813-822 (Pubitemid 34832606)
10. Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) Tc ell responses. J Clin Invest 2003;111:1673-1681
11. Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006;13:630-640
12. Kim JH, Majumder N, Lin H, Watkins S, Falo LD, Jr, You Z. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther 2005;16:1255-1266 (Pubitemid 41611653)
13. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002;20:2197-2207 (Pubitemid 34408812)
14. Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000;27:112-119
15. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12:3064-3069 (Pubitemid 43837352)
16. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-731 (Pubitemid 46224171)
17. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-3973
18. Morse MA, Clay TM, Hobeika AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005;11:3017-3024 (Pubitemid 40525207)
19. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169-4176 (Pubitemid 24980080)
20. Nockel J, van den Engel NK, Winter H, Hatz RA, Zimmermann W, Kammerer R. Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 Tantige n-transgenic mice with or without a human CEA transgene. BMC Cancer 2006;6:57.
21. Cusi MG, Del Vecchio MT, Terrosi C, et al. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. J Immunol 2005;174:7210-7216 (Pubitemid 40705689)
22. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006;103:17372-17377 (Pubitemid 44788976)
23. Naito Y, Saito K, Shiiba K, et al. CD8+ Tcells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494 (Pubitemid 28376536)
24. Hung CF, Cheng WF, He L, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003;63:2393-2398 (Pubitemid 36605174)
25. Pilon SA, Piechocki MP, Wei WZ. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 2001;167:3201-3206 (Pubitemid 32852559)
26. + T cell-mediated eradication of poorly immunogenic B16-10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004;109:499-506.
27. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 Tcell survival signal. J Immunol 1999;162:5037-5040 (Pubitemid 29307099)
28. Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 2007;125:76-87. (Pubitemid 47374542)
29. Wilczynski JR, Kalinka J, Radwan M. The role of T-regulatory cells in pregnancy and cancer. Front Biosci 2008;13:2275-2289
30. Marx J. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science 2008;319:154-156
31. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007;67:10019-10026 (Pubitemid 47621253)
32. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007;67:11021-11028
33. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008;111:219-228
34. He Y, Zhang J, Donahue C, Falo LD, Jr. Skin-derived dendritic cells induce potent CD8(+) Tce ll immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006;24:643-656
35. Spaner DE, Astsaturov I, Vogel T, et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 2006;106:890-899 (Pubitemid 43238457)